![]() ![]() The fusion of SPYMEG cells with antibody-producing cells collected from human blood facilitates extremely efficient and convenient acquisition of fully human antibody-producing hybridomas. SPYMEG is a fusion partner cell line developed to obtain fully human monoclonal antibodies in collaboration with Professor Naomasa Yamamoto at the School of Pharmaceutical Sciences, Ohu University. SPYMEG, Fusion Partner Cell Line for fully Human Monoclonal Antibodies In addition, it is possible to prepare antibody fragments (scFv and Fab), IgG proteins, etc. By selectively obtaining the specific antibody phage against a target molecule (antigen) from a population of antibody phages that bind to various molecules, our technology can thereby also obtain the gene of the target antibody. The phage contains the gene of the antibody displayed. An antibody phage displays antibody fragments (i.e., Fab and scFv) that have antigen-binding ability on fibrous phages of E. ![]() * A phage is a virus that infects specific bacteria. In addition, utilizing the advantages of the phage display method in finding rare antibodies, we are developing methods for obtaining antibodies against G protein-coupled receptors (GPCRs) or glycosylated epitope - which, despite being useful drug discovery targets, are very difficult to produce antibodies for - and methods for efficiently selecting antibodies from vast antibody libraries by Next Generation Sequencing (NGS) and data science. MBL owns a large number of human antibody libraries including 1 to 10 billion different antibodies, and we have succeeded in developing tumor-specific (suppressant) antibodies and virus neutralizing antibodies. The technology is also useful for producing antibodies against highly lethal toxins and viruses because it is possible to construct antibody libraries without the laboratory work of animal immunization with antigens. With this technology, vast antibody libraries including a very broad variety of antibodies can be constructed, so extremely rare and high affinity antibodies can be obtained quickly and efficiently. The phage display method is a procedure to obtain antibodies that bind to target molecules (antigens) by presenting antibodies (e.g., Fab scFv) to fibrous phages of E. Production of Human Monoclonal Antibodies by Phage Display Method * MBL employs the phage display method and fusion partner technology (using the fusion partner cell line, SPYMEG) to efficiently obtain human monoclonal antibodies as the “seeds” of antibody drugs by making the best use of the advantages of each of these technologies. There are different methods for producing fully human antibodies: phage display technology, immunization of humanized transgenic mice which are genetically engineered to produce fully human antibodies, sequencing analysis of antibody genes from human antibody-producing cells, and a technology to fuse antibody-producing cells and fusion partners. Since human antibodies are not recognized as foreign substances in the human body, they are considered to be highly effective and safe treatments. 22:1539-1545 (2004) (PubMed: 15568019) Human Monoclonal Antibody-Producing TechnologyĬurrently available antibody drugs include humanized antibodies and fully human antibodies generated from human genes. Also this MBL technology can provide antibodies with extremely high binding affinity.ġ) Suematsu S. In monoclonal antibody-production using this technology, the number of monoclonal antibodies obtained is more than 10 times larger than what can be done by conventional methods. When artificial lymph nodes formed in immunized mice are transplanted into immunodeficient mice, they are capable of producing an antibody titer for target antigens that is 10 to 100 times higher than that in normal mice. Normal lymph nodes contain immune cells that respond to various antigens, whereas artificial lymph nodes have a distinct feature in that they consist of only targeting antigen-specific immune cells. The technology was developed for the preparation of artificial lymph nodes in the kidney of mice. MBL’s artificial lymph node technology is a highly efficient antibody-production technology based on the method created by Professor Takeshi Watanabe at the National Research and Development Institute, RIKEN, and his associates. Recombinant Protein Production Technology.SPYMEG, Fusion Partner Cell Line for fully Human Monoclonal Antibodies.Production of Human Monoclonal Antibodies by Phage Display Method.Human Monoclonal Antibody-Producing Technology. ![]()
0 Comments
Leave a Reply. |